Treatment options for vulvovaginal candidiasis, 1993. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Treatment options for vulvovaginal candidiasis, 1993.

Clin Infect Dis. 1995 Apr;20 Suppl 1:S80-90. Unique Identifier : AIDSLINE MED/95315416
Reef SE; Levine WC; McNeil MM; Fisher-Hoch S; Holmberg SD; Duerr A; Smith D; Sobel JD; Pinner RW; Centers for Disease Control and Prevention, Emerging Bacterial; and Mycotic Diseases Branch, Atlanta, Georgia 30333, USA.

Abstract: Vulvovaginal candidiasis (VVC), the second most common form of vaginitis, particularly affects women of childbearing age. Since the 1970s, several new agents have become available for the treatment of VVC. This review focuses on options for the treatment of this condition, critically evaluating the relevant published studies. For the treatment of acute episodes of VVC in nonpregnant women, several topical and oral antifungal agents are clinically and mycologically effective. Topical agents should be considered the first line of therapy; however, oral agents are sometimes associated with better compliance among patients. For acute episodes in pregnant women, a topical agent is the treatment of choice. Until data become available on the treatment of VVC in women infected with human immunodeficiency virus (HIV), the same approach as that used for women without HIV infection should be considered as previously written. For recurrent VVC, the optimal maintenance therapy has not yet been established; however, administration of low-dose oral ketoconazole (100 mg/d) has proven effective. Well-designed studies of the best therapy for VVC in women with HIV infection and for recurrent VVC are urgently needed.
Keywords: Acute Disease Administration, Oral Administration, Topical Antibiotics/THERAPEUTIC USE Candidiasis, Vulvovaginal/COMPLICATIONS/*DRUG THERAPY Female Human HIV Infections/COMPLICATIONS Pregnancy Pregnancy Complications, Infectious/DRUG THERAPY Recurrence JOURNAL ARTICLE REVIEW REVIEW, TUTORIALKWDacutediseaseadministration,oraladministration,topicalantibiotics/therapeuticusecandidiasis,vulvovaginal/complications/KWDdrugtherapyfemalehumanhivinfections/complicationspregnancypregnancycomplications,infectious/drugtherapyrecurrencejournalarticlereviewreview,tutorial
951030
M95A0792

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .